A Study of SC-007 in Subjects With Advanced Cancer

Summary

This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.

Timeline

Start

2017-09-13

Primary completion

2018-03-20

Completion

2018-04-02

Outcome

Outcome not reported

Stopped: “Benefit/Risk Imbalance”

Drugs

Indications